LONDON--(EON: Enhanced Online News)--Technavio’s latest report on the global critical care therapeutics market provides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
“Plasma therapeutics are widely used in the management of critical care indications such as bleeding in surgical settings including cardiac surgery, pregnancy, postpartum hemorrhage, trauma, and perioperative bleeding. However, no consensus has yet been reached regarding dose, duration of therapy, and when to use these factor concentrates.”
Sapna Jha, a lead research analyst from Technavio, specializing in research on patient monitoring devices sector, says, “Plasma therapeutics are widely used in the management of critical care indications such as bleeding in surgical settings including cardiac surgery, pregnancy, postpartum hemorrhage, trauma, and perioperative bleeding. However, no consensus has yet been reached regarding dose, duration of therapy, and when to use these factor concentrates.”
China is the largest market for albumin products followed by the US market. Albumin is being used as a volume replacement therapy apart from being used for kidney diseases, cirrhosis, and cancer. However, the demand for plasma products, especially albumin and immunoglobulins, is outstripping the supply. This is because of the stringent regulations imposed on the supply of raw materials and a ban on the import of plasma products.
Request a sample report: http://www.technavio.com/request-a-sample?report=56181
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global patient monitoring devices market according to Technavio healthcare and life sciences research analysts are:
Increased development of recombinant products for critical care use
The development of recombinant products is increasing recently. Plasma fractionates such as albumin, fibrinogen, prothrombin and Factor XIII are obtained from the blood plasma. For this, blood may be collected from different individuals. This may result in the spread of various pathogenic infections through the blood. Also, the lack of blood donors for the development of albumin, fibrinogen, prothrombin and factor XIII by this source will limit the quantity of these products produced leading to a deficit in its quantity.
“Researchers are showing more interest in the development of a genetically engineered form of plasma products for the treatment of individuals with blood-related diseases and during surgeries,” according to Sapna.
Establishment of plasma fractionation facilities in emerging economies by global players
Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations.
In 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare, started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, it would drive global players to open a number of such facilities in the region.
Strategic initiatives of vendors fueling the market growth
Vendors are aggressively focusing on expanding their expertise and presence by implementing organic and inorganic growth strategies. Such initiatives will likely foster the business activities of the vendors in critical care therapeutics market leading to growth opportunities. For instance, in 2016, Shire completed the acquisition of Baxalta for a cash consideration of USD 32 billion.
The acquisition enabled Shire to become a leading company in providing products for bleeding disorders and rare diseases. Further, it will also allow the company to improve its operational and R&D expertise substantially. In March 2015, Grifols made a major equity investment of 45% in Alkahest to develop novel plasma-based products co-jointly.
The key vendors are as follows:
- CSL Behring
- Kedrion Biopharma
Browse Related Reports:
- Global Gastrointestinal Therapeutics Market 2016-2020
- Global Lung Cancer Therapeutics Market 2016-2020
- Global Leukemia Therapeutics Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like medical imaging, oncology, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.